COVAXIN
Kathmandu: Nepal has approved India's COVAXIN COVID-19 vaccine for emergency use, media reports said.
The vaccine has been developed by Bharat Biotech.
A meeting of the drug advisory committee of the Department of Drug Administration on Friday decided to issue a conditional emergency use authorisation to the vaccine, according to a press statement issued by the department on Friday as quoted by The Kathmandu Post.
Bharat Biotech, a global leader in vaccine innovation,developing vaccines for infectious diseases, earlier announced the first interim analysis of itsBBV152 (COVAXIN) where it showed it was 81 percent effective.
The whole virion inactivated COVID-19 vaccine candidate demonstratedan interim vaccine efficacy of 81% in its Phase 3 clinical trial," the company said in a statement.
The trials involved 25,800 subjects,the largest ever conducted in India, in partnership with the Indian Council of Medical Research.
“Today is an important milestone in vaccine discovery, for science and our fight againstcoronavirus. With today’s results from our Phase 3 clinical trials, we have now reported data onour COVID-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants.COVAXIN® demonstrates high clinical efficacy trend against COVID-19 but also significantimmunogenicity against the rapidly emerging variants,” said Dr. Krishna Ella, Chairman &Managing Director, Bharat Biotech.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
